MA33488B1 - Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn - Google Patents
Motifs de modification chimique pour des inhibiteurs et mimétiques de miarnInfo
- Publication number
- MA33488B1 MA33488B1 MA34505A MA34505A MA33488B1 MA 33488 B1 MA33488 B1 MA 33488B1 MA 34505 A MA34505 A MA 34505A MA 34505 A MA34505 A MA 34505A MA 33488 B1 MA33488 B1 MA 33488B1
- Authority
- MA
- Morocco
- Prior art keywords
- mimetics
- inhibitors
- mirik
- chemical modification
- modification rules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/332—Abasic residue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
Abstract
La présente invention concerne des polynucléotides ayant des motifs de chimie qui confèrent une stabilité, activité et/ou toxicité améliorée(s) par rapport à leur utilisation en tant qu'inhibiteurs de miARN ou mimétiques de miARN. L'invention concerne en outre des compositions pharmaceutiques et formulations comprenant les polynucléotides, et des procédés pour traiter des patients ayant une affection associée à l'expression de miARN ou d'ARNm.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18503309P | 2009-06-08 | 2009-06-08 | |
PCT/US2010/037821 WO2010144485A1 (fr) | 2009-06-08 | 2010-06-08 | Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33488B1 true MA33488B1 (fr) | 2012-08-01 |
Family
ID=43309198
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34505A MA33488B1 (fr) | 2009-06-08 | 2010-06-08 | Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn |
Country Status (17)
Country | Link |
---|---|
US (2) | US20120148664A1 (fr) |
EP (1) | EP2440566A4 (fr) |
JP (1) | JP2012529295A (fr) |
KR (1) | KR20120047892A (fr) |
CN (1) | CN102803284B (fr) |
AU (1) | AU2010258875A1 (fr) |
BR (1) | BRPI1010885A2 (fr) |
CA (1) | CA2765129A1 (fr) |
EA (1) | EA022757B1 (fr) |
GE (1) | GEP20156329B (fr) |
MA (1) | MA33488B1 (fr) |
MX (1) | MX2011013176A (fr) |
NZ (1) | NZ597078A (fr) |
SG (1) | SG176716A1 (fr) |
UA (1) | UA105390C2 (fr) |
WO (1) | WO2010144485A1 (fr) |
ZA (1) | ZA201109319B (fr) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008018795A1 (fr) | 2006-08-11 | 2008-02-14 | Prosensa Technologies B.V. | Procédés et moyens de traitement de troubles génétiques associés à l'instabilité des répétitions de l'ADN |
WO2009054725A2 (fr) | 2007-10-26 | 2009-04-30 | Academisch Ziekenhuis Leiden | Moyens et procédés pour contrebalancer des troubles musculaires |
EP2539357B1 (fr) | 2010-02-26 | 2017-06-14 | Memorial Sloan-Kettering Cancer Center | Procédés et compositions destinés à la détection et au traitement du cancer impliquant des miarn et des inhibiteurs des miarn ainsi que des cibles |
US20120116381A1 (en) | 2010-11-05 | 2012-05-10 | Houser Kevin L | Surgical instrument with charging station and wireless communication |
AU2011343720A1 (en) * | 2010-12-15 | 2013-04-11 | Miragen Therapeutics | MicroRNA inhibitors comprising locked nucleotides |
CN102643807B (zh) * | 2011-02-18 | 2015-06-03 | 中国科学院上海药物研究所 | 人miR-484的反义寡聚核苷酸及其应用 |
EP2699269A1 (fr) * | 2011-04-22 | 2014-02-26 | Prosensa Technologies B.V. | Nouveaux composés pour traiter, retarder et/ou prévenir un trouble génétique humain, tel que la dystrophie myotonique de type 1 (dm1) |
ES2868950T3 (es) * | 2011-04-25 | 2021-10-22 | Sanofi Sa | Compuestos de microARN y métodos para modular la actividad de miR-21 |
WO2012149646A1 (fr) * | 2011-05-05 | 2012-11-08 | Sunnybrook Research Institute | Inhibiteurs d'arnmi et leurs utilisations |
BR112013029016A2 (pt) * | 2011-05-09 | 2017-01-17 | Cambridge Entpr Ltd | métodos de modulação de micrornas no tratamento da hipertensão arterial pulmonar |
EP2763703B1 (fr) | 2011-10-06 | 2018-02-14 | Miragen Therapeutics, Inc. | Régulation de l'homéostasie énergétique du corps entier par la régulation de microarn |
ES2907250T3 (es) | 2012-01-27 | 2022-04-22 | Biomarin Tech Bv | Oligonucleótidos de modulación de ARN con características mejoradas para el tratamiento de la distrofia muscular de Duchenne y de Becker |
RS56319B1 (sr) | 2012-04-23 | 2017-12-29 | Biomarin Tech Bv | Oligonukleotidi koji moduliraju rnk sa poboljšanim karakteristikama za lečenje neuromišićnih poremećaja |
UA117098C2 (uk) | 2012-04-25 | 2018-06-25 | Рег'Юлес Терап'Ютікс Інк. | Сполука, що містить модифікований олігонуклеотид |
CN102703456B (zh) * | 2012-05-15 | 2014-04-02 | 武汉生命之美科技有限公司 | DAPK3基因hsa-miR-20a的作用靶位点 |
CA2876180C (fr) | 2012-06-21 | 2019-11-19 | MiRagen Therapeutics, Inc. | Inhibiteurs a base d'oligonucleotides comprenant un motif d'acide nucleique bloque |
US9163235B2 (en) | 2012-06-21 | 2015-10-20 | MiRagen Therapeutics, Inc. | Inhibitors of the miR-15 family of micro-RNAs |
UA116639C2 (uk) | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
CA2902623A1 (fr) * | 2013-03-15 | 2014-09-25 | MiRagen Therapeutics, Inc. | Inhibiteur d'acide nucleique verrouille de mir-145 et utilisations associees |
MX371093B (es) | 2013-05-01 | 2020-01-16 | Regulus Therapeutics Inc | Compuestos de microarn y metodos para modular al mir-122. |
CN103290011B (zh) * | 2013-05-16 | 2015-09-16 | 南京市妇幼保健院 | 与胎儿先天性心脏病相关的母体血清/血浆miRNA标志物mir-29c及其应用 |
CN103667441B (zh) * | 2013-09-10 | 2016-10-19 | 山西医科大学第一医院 | 一种Hsa-miR-145-5p试剂盒及其成熟体模拟物的应用 |
GB201400598D0 (en) | 2014-01-14 | 2014-03-05 | Univ Glasgow | Materials and methods for modulation of tendon healing |
CN104083761A (zh) * | 2014-06-25 | 2014-10-08 | 北京大学第三医院 | microRNA-101抑制剂在制备预防或治疗骨关节炎药物中的应用 |
MA40463A (fr) | 2014-08-07 | 2017-06-14 | Regulus Therapeutics Inc | Ciblage de micro-arn pour traiter des troubles métaboliques |
AU2016209386A1 (en) | 2015-01-20 | 2017-08-03 | MiRagen Therapeutics, Inc. | miR-92 inhibitors and uses thereof |
WO2017043490A1 (fr) * | 2015-09-07 | 2017-03-16 | 協和発酵バイオ株式会社 | Acide ribonucléique double brin possédant un effet amélioré d'induction de l'immunité naturelle |
JP2019512489A (ja) * | 2016-03-07 | 2019-05-16 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | マイクロrnaおよびその使用方法 |
US20190127736A1 (en) * | 2016-04-29 | 2019-05-02 | Aptamir Therapeutics, Inc. | Inhibition of mir-22 mirna by apt-110 |
WO2018079841A1 (fr) * | 2016-10-31 | 2018-05-03 | 国立大学法人岐阜大学 | Molécule d'acide nucléique double brin, et son utilisation |
AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
CN111918968B (zh) | 2018-03-14 | 2023-11-24 | 贝斯以色列女执事医疗中心 | Micro-RNA 22的抑制剂 |
US11015197B2 (en) | 2018-08-29 | 2021-05-25 | Korea Institute Of Science And Technology | Therapeutic agent for treating cancer comprising anti-miRNA-albumin composite |
CA3174286A1 (fr) | 2020-04-02 | 2021-10-07 | Robert PLACE | Inhibition ciblee a l'aide d'oligonucleotides modifies |
US20230265426A1 (en) * | 2020-07-23 | 2023-08-24 | Johann Wolfgang Goethe-Universität Frankfurt | Combinatorial inhibition of mirnas for treatment of heart failure |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
US5998203A (en) | 1996-04-16 | 1999-12-07 | Ribozyme Pharmaceuticals, Inc. | Enzymatic nucleic acids containing 5'-and/or 3'-cap structures |
US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
DE10049549A1 (de) * | 2000-10-06 | 2002-05-02 | Markus Hecker | Modulation der Transkription pro-inflammatorischer Genprodukte |
CA2533701A1 (fr) * | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Composes oligomeres et compositions utilisables pour moduler des petits arn non-codants |
EP2990410A1 (fr) * | 2004-08-10 | 2016-03-02 | Alnylam Pharmaceuticals Inc. | Oligonucléotides modifiés chimiquement |
CN101426912A (zh) * | 2005-08-17 | 2009-05-06 | 瑟纳治疗公司 | 介导rna干扰的化学修饰短干扰核酸分子 |
US20080287383A1 (en) * | 2007-03-02 | 2008-11-20 | Nastech Pharmaceutical Company Inc. | Nucleic acid compounds for inhibiting erbb gene expression and uses thereof |
AU2008306327B2 (en) * | 2007-10-04 | 2014-05-15 | Roche Innovation Center Copenhagen A/S | Micromirs |
MX2010005166A (es) * | 2007-11-09 | 2010-10-07 | Univ Texas | Micro arn de la familia mir-15 que modulan la sobrevivencia de cardiomiocitos y reparacion cardiaca. |
-
2010
- 2010-06-08 CA CA2765129A patent/CA2765129A1/fr not_active Abandoned
- 2010-06-08 KR KR1020127000345A patent/KR20120047892A/ko not_active Application Discontinuation
- 2010-06-08 GE GEAP201012527A patent/GEP20156329B/en unknown
- 2010-06-08 EA EA201171493A patent/EA022757B1/ru not_active IP Right Cessation
- 2010-06-08 MA MA34505A patent/MA33488B1/fr unknown
- 2010-06-08 MX MX2011013176A patent/MX2011013176A/es active IP Right Grant
- 2010-06-08 WO PCT/US2010/037821 patent/WO2010144485A1/fr active Application Filing
- 2010-06-08 US US13/377,076 patent/US20120148664A1/en not_active Abandoned
- 2010-06-08 UA UAA201200188A patent/UA105390C2/ru unknown
- 2010-06-08 JP JP2012515076A patent/JP2012529295A/ja active Pending
- 2010-06-08 BR BRPI1010885A patent/BRPI1010885A2/pt not_active IP Right Cessation
- 2010-06-08 NZ NZ597078A patent/NZ597078A/xx not_active IP Right Cessation
- 2010-06-08 SG SG2011090529A patent/SG176716A1/en unknown
- 2010-06-08 AU AU2010258875A patent/AU2010258875A1/en not_active Abandoned
- 2010-06-08 CN CN201080035109.9A patent/CN102803284B/zh not_active Expired - Fee Related
- 2010-06-08 EP EP20100786712 patent/EP2440566A4/fr not_active Withdrawn
-
2011
- 2011-12-19 ZA ZA2011/09319A patent/ZA201109319B/en unknown
-
2013
- 2013-08-22 US US13/973,594 patent/US20140066491A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2765129A1 (fr) | 2010-12-16 |
EA022757B1 (ru) | 2016-02-29 |
WO2010144485A1 (fr) | 2010-12-16 |
AU2010258875A1 (en) | 2012-01-19 |
EA201171493A1 (ru) | 2012-06-29 |
JP2012529295A (ja) | 2012-11-22 |
NZ597078A (en) | 2013-11-29 |
CN102803284A (zh) | 2012-11-28 |
KR20120047892A (ko) | 2012-05-14 |
SG176716A1 (en) | 2012-01-30 |
UA105390C2 (ru) | 2014-05-12 |
CN102803284B (zh) | 2015-11-25 |
MX2011013176A (es) | 2012-04-30 |
EP2440566A4 (fr) | 2013-10-16 |
EP2440566A1 (fr) | 2012-04-18 |
BRPI1010885A2 (pt) | 2015-09-22 |
GEP20156329B (en) | 2015-07-27 |
ZA201109319B (en) | 2013-02-27 |
US20120148664A1 (en) | 2012-06-14 |
US20140066491A1 (en) | 2014-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33488B1 (fr) | Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn | |
MY158757A (en) | Viral inhibitor composition for in vivo threpeutic use | |
MD20150043A2 (ro) | Inhibitori ai histon-demetilazelor | |
BR112012027509A8 (pt) | Composto pirazolil-quinoxalina inibidor de quinase, combinação, produto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e método | |
EA201070421A1 (ru) | Микрорибонуклеиновые кислоты | |
MX2013010795A (es) | 1,3 oxazinas como inhibidores de beta-secretasa 1 (bace 1) y/o la beta-secretasa 2 (beta 2). | |
MX2013013692A (es) | Halogenoalquil-1,3-oxazinas como inhibidores de beta secretasa 1 (bace1) y/o beta secretasa 2 (bace2). | |
EP2493464A4 (fr) | Méthylsulfonylméthane (msm) pour le traitement de micro-organismes résistants aux médicaments | |
MX2010014233A (es) | Compuestos quimicos 251. | |
MX2013004491A (es) | Boronatos como inhibidores de arginasa. | |
EA201190217A1 (ru) | Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение | |
EA201270666A1 (ru) | Соединения и фармацевтические композиции для снижения уровня мочевой кислоты | |
MX2013007957A (es) | 1,4-oxazinas como inhibidores de los genes de enzima de segmentacion de la proteina precursora amiloide del sitio beta 1 y/o (bace1 y/o bace2). | |
MX2009007345A (es) | Compuestos con (fenil sustituido), con restos de propenal, sus derivados, actividad biologica y uso del mismo. | |
UA113538C2 (xx) | Фторметил-5,6-дигідро-4h-$1,3]оксазини | |
MX2013014194A (es) | 1,3-tiazepinas fusionadas a ciclopropilo como inhibidores de beta-secretasa 1 (bace) y/o beta-secretasa 2 (bace 2). | |
WO2009036341A3 (fr) | Compositions et procédés liés à l'inhibition de la vih protéase | |
PH12014502541A1 (en) | 5-amino [1,4] thiazines as bace 1 inhibitors | |
PH12014502623A1 (en) | Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors | |
PT1981862E (pt) | Compostos relacionados com lantionina para o tratamento de doenças inflamatórias | |
WO2009097973A3 (fr) | Imidazopyridazines en tant qu'inhibiteurs de par1, leur production et leur utilisation en tant que médicaments | |
EP2073635A4 (fr) | Inhibiteurs de spiropipéridine macrocyclique de bêta-secrétase pour le traitement de la maladie d'alzheimer | |
MX2013002398A (es) | Inhibidores de beta-secretasa (base) para su uso en tratamiento de diabetes. | |
MA32061B1 (fr) | Triazolopyridazines en tant qu'inhibiteurs de par1, production de celles-ci, et utilisation en tant que médicaments | |
TW200603791A (en) | Compounds and compositions as cathepsin S inhibitors |